Resources

February 06, 2023

White paper: A proprietary mammalian suspension technology for scalable rAAV production: The Pro10™ cell line

Discover how the HEK293-derived Pro10™ cell line accelerates AAV vector production. This whitepaper explores a scalable, animal component-free platform that reduces process development time and costs, meeting growing clinical and commercial demands for gene therapies.

Download

Explore more

Insights

Advanced Therapies Conference Recap: Key Takeaways from Key CGT Fall Conferences

Our scientific and business teams at Viralgen have been crisscrossing the globe to get insights on our peers’ latest advances in cell and gene therapy – and to share our own. Here’s a quick rundown of what we heard during three key conferences in...

November 05, 2025

Resources

Webinar: What Comes Next? Industry Takeaways from FDA’s Cell and Gene Therapy Listening Session

The US Food and Drug Administration’s Office of Therapeutic Products (OTP) convened a public listening session on September 18, 2025, asking the cell and gene therapy (CGT) community how prior knowledge can be leveraged to accelerate the development...